Taken together, our findings provide compelling evidence that MMP-2 inhibition therapy may enhance the efficacy of anti-PD-L1-based immunotherapy by simultaneously reducing PD-L1 expression and improving TILs infiltration in COAD. Here, MMP2 is linked to colon adenocarcinoma.